A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma.

Protocol No
JNJ-68284528MMY2001
Principal Investigator
Parameswaran Hari
Phase
I/II
Summary
To investigate the use of a new, experimental drug called JNJ-68284528, in people with Multiple Myeloma
Description
A Phase 1b-2, Open-Label Study of JNJ-68284528, a CAR-T Therapy Directed against BCMA in rrMM
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: